Ukr.Biochem.J. 2020; Volume 92, Issue 4, Jul-Aug, pp. 77-84

doi: https://doi.org/10.15407/ubj92.04.077

Anti-inflammatory and hepatoprotective effects of polyherbal composition in patients with chronic cholecystitis

07.09.2020   Uncategorized   No comments

M. Gahramanova1,2, I. Khalilova3, A. Omarov3,
Ya. Susak4, M. Rudyk2, L. Skivka2*

1Nargiz Medical Center, Baku, Azerbaijan;
2ESC “Institute of Biology and Medicine”, Taras Shevchenko National University of Kyiv, Ukraine;
3Department of Life Sciences & Center for Cell Pathology Research, Khazar University, Baku, Azerbaijan;
4Bogomolets National Medical University, Kyiv, Ukraine;
*e-mail: realmed@i.com.ua

Received: 21 November 2019; Accepted: 15 May 2020

Herbal preparations are widely used in the complementary treatment of inflammatory diseases including hepatobiliary disorders, among which chronic cholecystitis is one of the most common. This study was aimed to investigate the effect of the water extract from polyherbal composition consisting of eight medicinal plants (Helichrysum arenarium, Mentha piperita, Calendula officinalis, Taraxacum officinale, Polygonum aviculare, Matricaria chamomilla, Portulaca oleracea, Hypericum perforatum) on biochemical and haematologic indices as well as on immune reactivity parameters in patients with chronic cholecystitis. It was found that  consumption of polyherbal tea during 45 days was followed by normalization of liver biochemical indices (serum level of cholesterol, alanine aminotransferase and  aspartate aminotransferase activity, total and unconjugated bilirubin levels and diminution of hematological (leukocytosis, increased erythrocyte sedimentation rate and neutrophil-to-lymphocyte ratio) and immunological (increased serum level of pro-inflammatory cytokines) signs of systemic inflammation in patients with hepatobiliary disorder. The results of the research showed that the studied polygerbal composition can be recommended as a component of the complementary therapy for patients with chronic cholecystitis.

Keywords: , , , , ,

References:

  1. Lammert F, Gurusamy K, Ko CW, Miquel JF, Méndez-Sánchez N, Portincasa P, van Erpecum KJ, van Laarhoven CJ, Wang DQ. Gallstones. Nat Rev Dis Primers. 2016;2(1):16024.  PubMed, CrossRef
  2. Kasprzak A, Szmyt M, Malkowski W, Przybyszewska W, Helak-Łapaj C, Seraszek-Jaros A, Surdacka A, Małkowska-Lanzafame A, Kaczmarek E. Analysis of immunohistochemical expression of proinflammatory cytokines (IL-1α, IL-6, and TNF-α) in gallbladder mucosa: comparative study in acute and chronic calculous cholecystitis. Folia Morphol (Warsz). 2015;74(1):65-72. PubMed, CrossRef
  3. Micić D, Stanković S, Lalić N, Đukić V, Polovina S. Prognostic Value of Preoperative Neutrophil-to-lymphocyte Ratio for Prediction of Severe Cholecystitis. J Med Biochem. 2018;37(2):121-127. PubMed, PubMedCentral
  4. Latief U, Ahmad R. Herbal remedies for liver fibrosis: A review on the mode of action of fifty herbs. J Tradit Complement Med. 2017;8(3):352-360. PubMed, PubMedCentral, CrossRef
  5. Farkhondeh T, Samarghandian S, Azimi-Nezhad M, Hozeifi S. The hepato-protective effects of Portulaca oleracea L. extract: review. Curr Drug Discov Technol. 2019;16(2):122-126. PubMed, CrossRef
  6. Iranshahy M, Javadi B, Iranshahi M, Jahanbakhsh SP, Mahyari S, Hassani FV, Karimi G. A review of traditional uses, phytochemistry and pharmacology of Portulaca oleracea L. J Ethnopharmacol. 2017;205:158-172. PubMed, CrossRef
  7. Yang Y, Zhang Z, Li S, Ye X, Li X, He K. Synergy effects of herb extracts: pharmacokinetics and pharmacodynamic basis. Fitoterapia. 2014;92:133-147.
    PubMed, PubMedCentral, CrossRef
  8. Gakhramanova M., Gakhramanov S. Collection of medicinal plants with hepatoprotective, choleretic and anti-inflammatory effects. Eurasian patent for invention no 201300492. Published 30.05.2014.
  9. Franck T, Kohnen S, Boudjeltia KZ, Van Antwerpen P, Bosseloir A, Niesten A, Gach O, Nys M, Deby-Dupont G, Serteyn D. A new easy method for specific measurement of active myeloperoxidase in human biological fluids and tissue extracts. Talanta. 2009;80(2):723-729.  PubMed, CrossRef
  10. George A, Chinnappan S, Choudhary Y, Bommu P, Sridhar M. Immunomodulatory activity of an aqueous extract of Polygonum minus huds on Swiss albino mice using carbon clearance assay. Asian Pac J Trop Dis. 2014;4(5):398-400. CrossRef
  11. Gakhramanova M, Molozhava O, Svyatetska V, Ostapchuk A, Skivka L. Phytochemical analysis and immunomodulatory effect of polyherbal preparation with hepatoprotective, choleretic and anti-inflammatory activity in vitro. Proc. IIІ Intern. Scientific Conf. “Microbiology and Immunology – the Development Outlook in the 21st century”. Kyiv, Ukraine, 2018. P. 133.
  12. Pak M, Lindseth G. Risk Factors for Cholelithiasis. Gastroenterol Nurs. 2016;39(4):297-309. PubMed, CrossRef
  13. Ahn KS, Yoon YS, Han HS, Cho JY. Use of Liver Function Tests as First-line Diagnostic Tools for Predicting Common Bile Duct Stones in Acute Cholecystitis Patients. World J Surg. 2016;40(8):1925-1931. PubMed, CrossRef
  14. Berman MD, Carey MC. Metastable and equilibrium phase diagrams of unconjugated bilirubin IXα as functions of pH in model bile systems: Implications for pigment gallstone formation. Am J Physiol Gastrointest Liver Physiol. 2015;308(1):G42-G55. PubMed, PubMedCentral, CrossRef
  15. Castro AM, Macedo-de la Concha LE, Pantoja-Meléndez CA. Low-grade inflammation and its relation to obesity and chronic degenerative diseases. Revista Médica del Hospital General de México. 2017; 80(2): 101-105. CrossRef
  16. Lee JS, Kim NY, Na SH, Youn YH, Shin CS. Reference values of neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, platelet-lymphocyte ratio, and mean platelet volume in healthy adults in South Korea. Medicine (Baltimore). 2018;97(26):e11138. PubMed, PubMedCentral, CrossRef
  17. Gadzhiev DzhN, Gadzhiev NDzh, Mamedova ZB. Features of cytokines profile in various forms of systemic inflammatory response syndrome in patients with acute calculous cholecystitis. Khirurgiia (Mosk). 2017;(10):61-64. (In Russian). PubMed, CrossRef
  18. Ghanemi A, St-Amand J. Interleukin-6 as a “metabolic hormone”. Cytokine. 2018;112:132-136. PubMed, CrossRef
  19. Hasegawa T, Hall CJ, Crosier PS, Abe G, Kawakami K, Kudo A, Kawakami A. Transient inflammatory response mediated by interleukin-1β is required for proper regeneration in zebrafish fin fold. Elife. 2017;6. pii: e22716.  PubMed, PubMedCentral, CrossRef
  20. Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50. PubMed, CrossRef
  21. Van Dyken SJ, Locksley RM. Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu Rev Immunol. 2013;31:317-343. PubMed, PubMedCentral, CrossRef
  22. Bonaventura A, Liberale L, Carbone F, Vecchié A, Diaz-Cañestro C, Camici GG, Montecucco F, Dallegri F. The Pathophysiological Role of Neutrophil Extracellular Traps in Inflammatory Diseases. Thromb Haemost. 2018;118(1):6-27. PubMed, CrossRef
  23. Coculescu BI, Dincă GV, Bălăeţ C, Manole G, Bălăeţ M, Stocheci CM. Myeloperoxidase, a possible biomarker for the early diagnosis of cardiac diastolic dysfunction with preserved ejection fraction. J Enzyme Inhib Med Chem. 2018;33(1):1292-1298.  PubMed, PubMedCentral, CrossRef
  24. Ward NS, Casserly B, Ayala A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med. 2008;29(4):617-625.  PubMed, PubMedCentral, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.